Arbutus Biopharma Corp (ABUS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically developing imdusiran (an RNAi therapeutic) and AB-101 (an oral PD-L1 inhibitor) for chronic hepatitis B (cHBV). The company is also heavily engaged in intellectual property litigation regarding its lipid nanoparticle (LNP) technology.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Total Revenue | $1.0 million | $180.1 million | $12.5 million |
| Net Income (Loss) | $(5.1) million | $164.6 million | $(22.0) million |
| Operating Expenses | $7.0 million | $17.2 million | $36.7 million |
| Cash & Equivalents | $19.2 million | $19.2 million | $37.4 million |
| Total Liquid Assets | (Cash + Marketable Securities) | ||
| Total Liquid Assets | $92.6 million | $92.6 million | $91.5 million |
| Debt | No outstanding debt. |
Revenue Composition (YTD 2026): The vast majority of revenue ($179.4 million) stems from a non-cash receivable related to the settlement with Genevant/Moderna. Recurring revenue from collaborations and royalties was minimal ($0.8 million).
Material Changes vs. Prior Period
- Revenue Surge: YTD revenue increased by $167.6 million compared to the prior year, driven almost entirely by the recognition of $178.4 million in revenue from the Moderna settlement agreement (recorded as a receivable in Q2).
- Profitability Shift: The company swung from a net loss of $22.0 million in YTD 2025 to a net income of $164.6 million in YTD 2026 due to the settlement revenue. Excluding this one-time item, the company remains in an operating loss position.
- Expense Reduction: Operating expenses decreased significantly ($19.5 million reduction YTD) due to workforce reductions and the discontinuation of in-house scientific research implemented in early 2025.
- Qilu Partnership Termination: The strategic partnership with Qilu Pharmaceutical was terminated in June 2025, resulting in the recognition of remaining deferred revenue in the prior year, which contrasts with the lack of Qilu revenue in the current period.
Guidance, Outlook, and Risks
- Moderna Settlement: On July 8, 2026 (post-period end), the company received $178.4 million in cash from the noncontingent settlement payment. A contingent payment of up to $1.3 billion remains possible pending the outcome of a specific appeal by Moderna regarding 28 U.S.C. § 1498.
- Liquidity: Management states it has sufficient cash resources to fund operations for at least the next 12 months. The company is evaluating a return of capital to shareholders in Q3 2026.
- Development Progress:
- Imdusiran: Received FDA Fast Track designation in April 2026. Alignment reached with FDA on Phase 2b trial design in May 2026.
- AB-101: Completed Phase 1a/1b trial; data showed high receptor occupancy and HBsAg decline in some patients.
- Legal Risks:
- Pfizer/BioNTech: Ongoing litigation in the U.S. and new international lawsuits filed in July 2026 regarding LNP technology infringement.
- European Patents: The EPO Board of Appeal revoked the '254 Patent in January 2026; the company plans to petition for review. However, the company does not expect this to impact U.S. litigation outcomes.
Investor Verification Checklist
- Cash Receipt Confirmation: Verify the actual receipt of the $178.4 million settlement payment in Q3 2026 cash flow statements, as it was recorded as a receivable in Q2.
- Contingent Payment Probability: Assess the likelihood of the $1.3 billion contingent payment based on the status of the Moderna § 1498 appeal.
- Return of Capital: Monitor announcements regarding the potential special dividend or share buyback in Q3 2026.
- Phase 2b Trial Initiation: Confirm the start date and enrollment progress of the imdusiran Phase 2b trial following FDA alignment.
- European Patent Status: Track the outcome of the petition for review regarding the revoked '254 Patent and its potential impact on global IP strategy.